Concepedia

LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

M-J. Ahn, Aaron Lisberg, Luis Paz‐Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons‐Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, M. Pérol,

Annals of Oncology · 2023 · 55 citations · 2 references

DOIFull text

Open access

Concepts

References

2

LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

B.C. Cho, Enriqueta Felip, Alexander I. Spira et al. · Annals of Oncology · 2023 · 83 citations · Full text

, , +13

LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

M-J. Ahn, Aaron Lisberg, Luis Paz‐Ares et al. · Annals of Oncology · 2023 · 55 citations · Full text

, , +12